Application of PD-L1, PD-L2, CD30, CD23 and BCL-6 in Diagnosis and Prognostic Evaluation of Primary Mediastinal Large B-cell Lymphoma

Objective To explore the application value of treatment-related markers PD-L1, PD-L2, CD30, CD23, BCL-2, BCL-6, MUM1 and GATA3 in the diagnosis and prognostic evaluation of primary mediastinal B-cell lymphoma(PMBL). Methods A retrospective study was conducted on 34 patients diagnosed with PMBL, and...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	YUAN Ting, CAO Zheng, LIU Xiuyun, ZHENG Bo, FENG Xiaoli
Formato:	article
Lenguaje:	ZH
Publicado:	Magazine House of Cancer Research on Prevention and Treatment 2021
Materias:	lymphoma mediastinum immunohistochemistry pd-l1 pd-l2 cd30 cd23 bcl-6 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/83fbdd36e92f4720acb2da0f5986a5ef
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:83fbdd36e92f4720acb2da0f5986a5ef
record_format	dspace
spelling	oai:doaj.org-article:83fbdd36e92f4720acb2da0f5986a5ef2021-11-05T02:22:52ZApplication of PD-L1, PD-L2, CD30, CD23 and BCL-6 in Diagnosis and Prognostic Evaluation of Primary Mediastinal Large B-cell Lymphoma1000-857810.3971/j.issn.1000-8578.2021.21.0307https://doaj.org/article/83fbdd36e92f4720acb2da0f5986a5ef2021-10-01T00:00:00Zhttp://html.rhhz.net/ZLFZYJ/html/8578.2020.21.0307.htmhttps://doaj.org/toc/1000-8578Objective To explore the application value of treatment-related markers PD-L1, PD-L2, CD30, CD23, BCL-2, BCL-6, MUM1 and GATA3 in the diagnosis and prognostic evaluation of primary mediastinal B-cell lymphoma(PMBL). Methods A retrospective study was conducted on 34 patients diagnosed with PMBL, and 31 patients with DLBCL-NOS which was not primary in the mediastinum were taken as control group. The expressions of 8 proteins were detected by IHC staining. Results The median percentages of tumor cells with PD-L1, PD-L2 and CD30 expression in PMBL group were 70% (30%, 90%), 25% (0, 70%) and 17.5% (0, 60%) respectively, which were significantly higher than those in the DLBCL-NOS group (P < 0.05). The positive rates of CD30 and CD23 in PMBL group were 61.76% (21/34) and 76.47% (26/34) respectively, significantly different with those in the DLBCL-NOS group (P=0.000). The survival curve of PMBL patients with CD30 or BCL-6 expression showed a trend of poor prognosis, despite the P value was > 0.05. Conclusion The high expression levels of PD-L1, PD-L2 and CD30 in PMBL are helpful to accurately identify more patients who may respond to immune or targeted therapy. Immunohistochemical staining of PD-L1, PD-L2, CD30 and CD23 is helpful for the differential diagnosis of PMBL and DLBCL-NOS. As candidate prognostic indicators of PMBL, CD30 and BCL-6 should be further studied in a larger number of samples.YUAN TingCAO ZhengLIU XiuyunZHENG BoFENG XiaoliMagazine House of Cancer Research on Prevention and Treatmentarticlelymphomamediastinumimmunohistochemistrypd-l1pd-l2cd30cd23bcl-6Neoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ZHZhongliu Fangzhi Yanjiu, Vol 48, Iss 10, Pp 941-946 (2021)
institution	DOAJ
collection	DOAJ
language	ZH
topic	lymphoma mediastinum immunohistochemistry pd-l1 pd-l2 cd30 cd23 bcl-6 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	lymphoma mediastinum immunohistochemistry pd-l1 pd-l2 cd30 cd23 bcl-6 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 YUAN Ting CAO Zheng LIU Xiuyun ZHENG Bo FENG Xiaoli Application of PD-L1, PD-L2, CD30, CD23 and BCL-6 in Diagnosis and Prognostic Evaluation of Primary Mediastinal Large B-cell Lymphoma
description	Objective To explore the application value of treatment-related markers PD-L1, PD-L2, CD30, CD23, BCL-2, BCL-6, MUM1 and GATA3 in the diagnosis and prognostic evaluation of primary mediastinal B-cell lymphoma(PMBL). Methods A retrospective study was conducted on 34 patients diagnosed with PMBL, and 31 patients with DLBCL-NOS which was not primary in the mediastinum were taken as control group. The expressions of 8 proteins were detected by IHC staining. Results The median percentages of tumor cells with PD-L1, PD-L2 and CD30 expression in PMBL group were 70% (30%, 90%), 25% (0, 70%) and 17.5% (0, 60%) respectively, which were significantly higher than those in the DLBCL-NOS group (P < 0.05). The positive rates of CD30 and CD23 in PMBL group were 61.76% (21/34) and 76.47% (26/34) respectively, significantly different with those in the DLBCL-NOS group (P=0.000). The survival curve of PMBL patients with CD30 or BCL-6 expression showed a trend of poor prognosis, despite the P value was > 0.05. Conclusion The high expression levels of PD-L1, PD-L2 and CD30 in PMBL are helpful to accurately identify more patients who may respond to immune or targeted therapy. Immunohistochemical staining of PD-L1, PD-L2, CD30 and CD23 is helpful for the differential diagnosis of PMBL and DLBCL-NOS. As candidate prognostic indicators of PMBL, CD30 and BCL-6 should be further studied in a larger number of samples.
format	article
author	YUAN Ting CAO Zheng LIU Xiuyun ZHENG Bo FENG Xiaoli
author_facet	YUAN Ting CAO Zheng LIU Xiuyun ZHENG Bo FENG Xiaoli
author_sort	YUAN Ting
title	Application of PD-L1, PD-L2, CD30, CD23 and BCL-6 in Diagnosis and Prognostic Evaluation of Primary Mediastinal Large B-cell Lymphoma
title_short	Application of PD-L1, PD-L2, CD30, CD23 and BCL-6 in Diagnosis and Prognostic Evaluation of Primary Mediastinal Large B-cell Lymphoma
title_full	Application of PD-L1, PD-L2, CD30, CD23 and BCL-6 in Diagnosis and Prognostic Evaluation of Primary Mediastinal Large B-cell Lymphoma
title_fullStr	Application of PD-L1, PD-L2, CD30, CD23 and BCL-6 in Diagnosis and Prognostic Evaluation of Primary Mediastinal Large B-cell Lymphoma
title_full_unstemmed	Application of PD-L1, PD-L2, CD30, CD23 and BCL-6 in Diagnosis and Prognostic Evaluation of Primary Mediastinal Large B-cell Lymphoma
title_sort	application of pd-l1, pd-l2, cd30, cd23 and bcl-6 in diagnosis and prognostic evaluation of primary mediastinal large b-cell lymphoma
publisher	Magazine House of Cancer Research on Prevention and Treatment
publishDate	2021
url	https://doaj.org/article/83fbdd36e92f4720acb2da0f5986a5ef
work_keys_str_mv	AT yuanting applicationofpdl1pdl2cd30cd23andbcl6indiagnosisandprognosticevaluationofprimarymediastinallargebcelllymphoma AT caozheng applicationofpdl1pdl2cd30cd23andbcl6indiagnosisandprognosticevaluationofprimarymediastinallargebcelllymphoma AT liuxiuyun applicationofpdl1pdl2cd30cd23andbcl6indiagnosisandprognosticevaluationofprimarymediastinallargebcelllymphoma AT zhengbo applicationofpdl1pdl2cd30cd23andbcl6indiagnosisandprognosticevaluationofprimarymediastinallargebcelllymphoma AT fengxiaoli applicationofpdl1pdl2cd30cd23andbcl6indiagnosisandprognosticevaluationofprimarymediastinallargebcelllymphoma
_version_	1718444537795313664

Application of PD-L1, PD-L2, CD30, CD23 and BCL-6 in Diagnosis and Prognostic Evaluation of Primary Mediastinal Large B-cell Lymphoma

Ejemplares similares